P/E của cổ phiếu LNTH là bao nhiêu?

Lantheus Holdings Inc (LNTH) hiện giao dịch ở mức P/E 23.57 lần.

ROE của cổ phiếu LNTH là bao nhiêu?

Lantheus Holdings Inc có tỷ suất lợi nhuận trên vốn chủ sở hữu (ROE) 23.02%.

Tỷ suất cổ tức của LNTH là bao nhiêu?

Lantheus Holdings Inc có tỷ suất cổ tức 0.00%.

Điểm chất lượng (Quality Score) của LNTH là bao nhiêu?

AI của chúng tôi đánh giá chất lượng tài chính tổng thể của LNTH ở mức 77/100, dựa trên khả năng sinh lời, tăng trưởng, nợ và độ ổn định lợi nhuận.

Bây giờ có nên mua cổ phiếu LNTH không?

Điểm AI Timing của LNTH là 71/100, thể hiện mức độ hấp dẫn tương đối của giá hiện tại theo tín hiệu kỹ thuật và momentum — nên cân nhắc cùng điểm chất lượng và kế hoạch đầu tư của bạn.

Cổ phiếu LNTH thuộc ngành nào?

Lantheus Holdings Inc được xếp vào ngành Healthcare >> Drug Manufacturers - Specialty & Generic trên sàn NASDAQ

Cổ phiếu LNTH (NASDAQ) | LANTHEUS HOLDINGS INC

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

LNTH AI Analysis Summary

Our AI summary for LNTH: Lantheus Holdings Inc (NASDAQ), Healthcare >> Drug Manufacturers - Specialty & Generic sector. The stock currently trades at a P/E of 23.57, ROE of 23.02%, a dividend yield of 0.00%. Its financial Quality Score stands at 77/100 — mid-range fundamentals relative to the market. The AI Timing Score is 71/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

LNTH

Lantheus Holdings Inc

USD 99.64

-1.36 (-1.35%) Day Change

Watchlist Portfolio Compare Chart

23.57

P/E

0.47

D/E

23.0%

ROE

11.9%

ROA

0.00%

Div Yield

0.07

PEG

LANTHEUS HOLDINGS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 99.64 Price -1.36 (-1.35%) Day Change	NEWS SCORE: 98

LNTH Chất lượng tổng thể của cố phiếu Tốt ( Chất lượng = 77) và Thời điểm mua ...(Sign In to See)...

Loading chart...

77 QUALITY

Signal: OUTPERFORM

Signal Description: Company financial health is Good

Reason: Tăng trưởng ROE là âm trong năm ngoái.
ROA quá thấp so với ROE
Tăng trưởng ROA dưới mức tiêu chí của chúng tôi trong năm vừa qua

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt lắm , Sức khỏe tài chính Không tốt lắm , và khả năng kiếm lợi nhuận Tốt , ...

Yếu tố Chất lượng

58%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	98
Magic Formula Rank by ROA	1024
Magic Formula Rank by ROE	1024
Magic Formula Rank by ROIC	1059
Price	99.64
PBV / Sector	5.42 / 3.22
Earning Per Share	4.23

PE / Sector	23.57 / 29.79
PEG or PE/Growth / Sector	0.07 / 0.13 GREAT
Average 1M Daily Value	94.71 M
Average 1W Daily Value	138.33 M GREAT

Yếu tố Kỹ thuật

14%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Sức khỏe tài chính

56%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Khả năng kiếm lợi nhuận

70%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	18.05 / 15.21 GOOD
NPM Average (%) / Sector	16.35 / -10.83 GREAT
NPM Change Average (%) / Sector	178.45 / 117.42 GREAT
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	11.89 / 8.15
ROA Average (%) / Sector	12.01 / 2.87
ROA Change Average (%) / Sector	197.73 / 112.70 GREAT
ROE (%) / Sector	23.02 / -1.02 GOOD
ROE Average (%) / Sector	23.90 / 8.35 GOOD
ROE Change Average (%) / Sector	122.90 / 385.91 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Lợi tức cho nhà đầu tư

Dividend (%) / Sector	N/A / 0.51
Dividend Average (%) / Sector	N/A / 3.06
Dividend Change Average (%) / Sector	N/A / 13.64

Chi tiết đăng ký

Analyze Date	2026-08-01 08:00:07
Symbol	LNTH
Name	LANTHEUS HOLDINGS INC
Sector	Healthcare >> Drug Manufacturers - Specialty & Generic
Market	NASDAQ
Listed Shares	65.11 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	6,575.71 / 10,754.62

Tin tức, Dự báo ước tính

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 201 Burlington Road, Bedford, MA, United States, 01730

Phone: 978 671 8001

Website: https://www.lantheus.com

Employees: 1,193

Sector: Healthcare >> Drug Manufacturers - Specialty & Generic

Description: Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; LNTH-250; LNTH-2515; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; Curium Pharma; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.